Cargando…

LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway

For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment. However, most patients who initially responded to EGFR-TKIs eventually dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chunsheng, Zhou, Anting, Hu, Xin, Xiang, Yu, Huang, Mengjun, Huang, Jiuhong, Yang, Donglin, Tang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658955/
https://www.ncbi.nlm.nih.gov/pubmed/36362025
http://dx.doi.org/10.3390/ijms232113237
_version_ 1784830081754988544
author Hu, Chunsheng
Zhou, Anting
Hu, Xin
Xiang, Yu
Huang, Mengjun
Huang, Jiuhong
Yang, Donglin
Tang, Yan
author_facet Hu, Chunsheng
Zhou, Anting
Hu, Xin
Xiang, Yu
Huang, Mengjun
Huang, Jiuhong
Yang, Donglin
Tang, Yan
author_sort Hu, Chunsheng
collection PubMed
description For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment. However, most patients who initially responded to EGFR-TKIs eventually developed acquired resistance, limiting the effectiveness of therapy. It has long been known that epithelial–mesenchymal transition (EMT) leads to acquired resistance to EGFR-TKIs in NSCLC. However, the mechanisms underlying the resistance dependent on EMT are unknown. This research aimed to reveal the effects of LMNA in the regulation of acquired resistance to erlotinib by EMT in NSCLC. The acquired erlotinib-resistant cells (HCC827/ER) were induced by gradual increase of concentrations of erlotinib in erlotinib-sensitive HCC827 cells. RNA sequencing and bioinformatics analysis were performed to uncover the involvement of LMNA in the EMT process that induced acquired resistance to erlotinib. The effect of LMNA on cell proliferation and migration was measured by clone-formation, wound-healing, and transwell assays, respectively. The EMT-related protein, nuclear shape and volume, and cytoskeleton changes were examined by immunofluorescence. Western blot was used to identify the underlying molecular mechanism of LMNA regulation of EMT. HCC827/ER cells with acquired resistance to erlotinib underwent EMT and exhibited lower LMNA expression compared to parental sensitive cells. LMNA negatively regulated the expression of EMT markers; HCC827/ER cells showed a significant up-regulation of mesenchymal markers, such as CDH2, SNAI2, VIM, ZEB1, and TWIST1. The overexpression of LMNA in HCC827/ER cells significantly inhibited EMT and cell proliferation, and this inhibitory effect of LMNA was enhanced in the presence of 2.5 μM erlotinib. Furthermore, a decrease in LMNA expression resulted in a higher nuclear deformability and cytoskeletal changes. In HCC827/ER cells, AKT, FGFR, ERK1/2, and c-fos phosphorylation levels were higher than those in HCC827 cells; Furthermore, overexpression of LMNA in HCC827/ER cells reduced the phosphorylation of AKT, ERK1/2, c-fos, and FGFR. In conclusion, our findings first demonstrated that downregulation of LMNA promotes acquired EGFR-TKI resistance in NSCLC with EGFR mutations by EMT. LMNA inhibits cell proliferation and migration of erlotinib-resistant cells via inhibition of the FGFR/MAPK/c-fos signaling pathway. These findings indicated LMNA as a driver of acquired resistance to erlotinib and provided important information about the development of resistance to erlotinib treatment in NSCLC patients with EGFR mutations.
format Online
Article
Text
id pubmed-9658955
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96589552022-11-15 LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway Hu, Chunsheng Zhou, Anting Hu, Xin Xiang, Yu Huang, Mengjun Huang, Jiuhong Yang, Donglin Tang, Yan Int J Mol Sci Article For patients exhibiting non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a first-line treatment. However, most patients who initially responded to EGFR-TKIs eventually developed acquired resistance, limiting the effectiveness of therapy. It has long been known that epithelial–mesenchymal transition (EMT) leads to acquired resistance to EGFR-TKIs in NSCLC. However, the mechanisms underlying the resistance dependent on EMT are unknown. This research aimed to reveal the effects of LMNA in the regulation of acquired resistance to erlotinib by EMT in NSCLC. The acquired erlotinib-resistant cells (HCC827/ER) were induced by gradual increase of concentrations of erlotinib in erlotinib-sensitive HCC827 cells. RNA sequencing and bioinformatics analysis were performed to uncover the involvement of LMNA in the EMT process that induced acquired resistance to erlotinib. The effect of LMNA on cell proliferation and migration was measured by clone-formation, wound-healing, and transwell assays, respectively. The EMT-related protein, nuclear shape and volume, and cytoskeleton changes were examined by immunofluorescence. Western blot was used to identify the underlying molecular mechanism of LMNA regulation of EMT. HCC827/ER cells with acquired resistance to erlotinib underwent EMT and exhibited lower LMNA expression compared to parental sensitive cells. LMNA negatively regulated the expression of EMT markers; HCC827/ER cells showed a significant up-regulation of mesenchymal markers, such as CDH2, SNAI2, VIM, ZEB1, and TWIST1. The overexpression of LMNA in HCC827/ER cells significantly inhibited EMT and cell proliferation, and this inhibitory effect of LMNA was enhanced in the presence of 2.5 μM erlotinib. Furthermore, a decrease in LMNA expression resulted in a higher nuclear deformability and cytoskeletal changes. In HCC827/ER cells, AKT, FGFR, ERK1/2, and c-fos phosphorylation levels were higher than those in HCC827 cells; Furthermore, overexpression of LMNA in HCC827/ER cells reduced the phosphorylation of AKT, ERK1/2, c-fos, and FGFR. In conclusion, our findings first demonstrated that downregulation of LMNA promotes acquired EGFR-TKI resistance in NSCLC with EGFR mutations by EMT. LMNA inhibits cell proliferation and migration of erlotinib-resistant cells via inhibition of the FGFR/MAPK/c-fos signaling pathway. These findings indicated LMNA as a driver of acquired resistance to erlotinib and provided important information about the development of resistance to erlotinib treatment in NSCLC patients with EGFR mutations. MDPI 2022-10-31 /pmc/articles/PMC9658955/ /pubmed/36362025 http://dx.doi.org/10.3390/ijms232113237 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hu, Chunsheng
Zhou, Anting
Hu, Xin
Xiang, Yu
Huang, Mengjun
Huang, Jiuhong
Yang, Donglin
Tang, Yan
LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
title LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
title_full LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
title_fullStr LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
title_full_unstemmed LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
title_short LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial–Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway
title_sort lmna reduced acquired resistance to erlotinib in nsclc by reversing the epithelial–mesenchymal transition via the fgfr/mapk/c-fos signaling pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658955/
https://www.ncbi.nlm.nih.gov/pubmed/36362025
http://dx.doi.org/10.3390/ijms232113237
work_keys_str_mv AT huchunsheng lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT zhouanting lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT huxin lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT xiangyu lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT huangmengjun lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT huangjiuhong lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT yangdonglin lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway
AT tangyan lmnareducedacquiredresistancetoerlotinibinnsclcbyreversingtheepithelialmesenchymaltransitionviathefgfrmapkcfossignalingpathway